CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award SVP & Chief Commercial Officer acquired 30,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 200,000 shares (grant or award)
- 4 Grant or award EVP & Chief Financial Officer acquired 70,000 shares (grant or award)
- 4 Grant or award SVP, General Counsel & Sec. acquired 30,000 shares (grant or award)
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale SVP & Chief Medical Officer sold 16,300 shares at $15.51 ($252,776)
- 4 Open-market sale SVP, General Counsel & Sec. sold 10,900 shares at $15.51 ($169,090)
- 4 Exercise or conversion SVP & Chief Commercial Officer acquired 20,000 shares (option exercise)
- 4 Open-market sale SVP, CFO & Treasurer sold 10,895 shares at $15.51 ($169,013)
- 4 Open-market sale President and CEO sold 23,330 shares at $15.48 ($361,242)
- 4 Open-market sale 10% owner sold 1,120,461 shares at an average $16.56 ($18,559,971)
- 4 Open-market sale 10% owner sold 547,886 shares at an average $15.66 ($8,582,621)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 12 of 29 · 579 filings